The weeklystochastics oscillatorhas turned higher at theoversoldlevel but not crossed into a buy cycle. This positioning could presage a small or aborted fifth wave, briefly undercutting the prior low in a selling climax. A bounce above the October low at $182.35 would then issue abuying signal...
When Novartis’ wet age-related macular degeneration (AMD) med Beovu crossed the FDA’s finish line, it seemed to pose a formidable threat to Regeneron’s megablockbuster Eylea and Roche’s Lucentis. But its foes had one card left to play: Beovu carried greater safety risks. And that hamper...